OHMX.Bio provides a complete R&D platform to help customers resolve their biological questions through cutting-edge technologies in different -omics fields: (epi)genomics, transcriptomics, translatomics and proteomics. Current flagships in portfolio are ribosome profiling and third generation sequencing.
With its in-house developed high performant ribosome profiling service, OHMX.bio provides a genome-wide assessment of mRNA targeted by translating ribosomes. This highly sensitive sequencing-based technology unravels the translatome, a snapshot of RNA that is being translated. Quantification of gene-specific translation, discovery of non-canonical translation events, investigation of ribosome elongation speed and pausing, figuring out translation regulation by microRNAs and RNA-binding proteins and/or determination of mechanisms related to translation initiation and termination, are made possible.
OHMX.bio also services third generation sequencing workflows based on the Oxford Nanopore Technology. Direct DNA and RNA solutions allow for amplification-free sequencing of (ultra-)long reads and additionally allow to map their epigenetic features. Applications are everywhere, in the fields of clinical and more specifically cancer research, environmental and plant research, microbiology and microbiome analysis, genome and transcriptome research.
With its in-house developed high performant ribosome profiling service, OHMX.bio provides a genome-wide assessment of mRNA targeted by translating ribosomes. This highly sensitive sequencing-based technology unravels the translatome, a snapshot of RNA that is being translated. Quantification of gene-specific translation, discovery of non-canonical translation events, investigation of ribosome elongation speed and pausing, figuring out translation regulation by microRNAs and RNA-binding proteins and/or determination of mechanisms related to translation initiation and termination, are made possible.
OHMX.bio also services third generation sequencing workflows based on the Oxford Nanopore Technology. Direct DNA and RNA solutions allow for amplification-free sequencing of (ultra-)long reads and additionally allow to map their epigenetic features. Applications are everywhere, in the fields of clinical and more specifically cancer research, environmental and plant research, microbiology and microbiome analysis, genome and transcriptome research.
Employees: 1-10
Founded date: 2019
Investors 1
| Date | Name | Website |
| - | Novalis Bi... | noval.is |
Mentions in press and media 1
| Date | Title | Description |
| 08.08.2024 | Anacura acquires OHMX.bio, a Novalis fund I portfolio company, and extends its service with multi-omics for drug discovery and diagnostics | July 4th, 2024. Ghent, Belgium Anacura acquires OHMX.bio, a Novalis fund I portfolio company, and extends its service with multi-omics for drug discovery and diagnostics |